Neuroscientists will no longer attempt for new research in mental disorders, states a news report. The leading drug companies like UK-based GlaxoSmithKline (GSK) and AstraZeneca declared that they will not work on the psychiatric medication in the treatments like depression, dysthymia and schizophrenia. This announcement is a setback to millions of people who suffer from such problems.

Economic and social forces are the main reasons behind the discontinuing of the progress work in the research area. Some very expensive drugs were under experimentation and their success in the treatments was not sure, said Andrew Witty, Chief Executive, GSK.

A report prepared for the European College of Neuropsychopharmacology (ECNP) states that immediate action should be taken to overcome the fiscal problems in the research of mental disorders. This report was prepared by Guy Goodwin, Professor of Psychiatry at Oxford University and David Nutt, Professor of Neuropsychopharmacology at Imperial College London who are worried about the discontinuing of the research work.

Prof Nutt said, "Despite the public health imperative, not only has EU research funding remained very low, but – even worse – big pharma is increasingly coming to see research into better neuropsychiatric drug targets as economically non-viable".